Skip to main content
PredictPedia
Market snapshot: . Prices may have changed since this snapshot.
Events
GroupPOLYMARKET

FDA moves BPC-157 to Category 1 by…?

FDA moves BPC-157 to Category 1 by…?
Vol

PM $4.8K

|
Events

1

|
Markets

1

Polymarket

Current odds

Snapshot from

As of Oct 21, 2026, 12:00 AM UTC, the highest-priced outcome on Polymarket is December 31, 2026 at 48.5%.

Polymarket

  1. December 31, 202648.5%

Yes prices. They are not order quotes; check each platform's rules, fees and live prices before trading.

AI Analysis

Trader mode: Market mechanics, assumptions and risks

PM $4.8K

Reported volume · provider units

1

Saved contracts

0

Same-question pairs

Source snapshot: Oct 21, 2026, 12:00 AM UTC

About This Event

This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”. A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify. Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date. A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify. The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.

AI-generated analysis based on market data. Not financial advice.

AI-written background. References identify the evidence used; Wikipedia links under Learn More are additional reading. Prices and provider rules are dated snapshots. This is not financial advice.

Related prediction markets

Prices are catalog snapshots and may have changed. Check each market's rules and observation time.

KalshiHealth
When will the FDA reclassify BPC-157 to Category 1?

When will the FDA reclassify BPC-157 to Category 1?

K 39.5K contracts
When will FDA announce Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List? (Before 2027)Yes 28%
When will FDA announce Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List? (Before November)Yes 14%
2 mktsNext deadline Nov 8, 2026 UTC
KalshiHealth
Will the FDA approve MDMA for PTSD?

Will the FDA approve MDMA for PTSD?

K 13.1K contracts
Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2032?Yes 49%
Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2031?Yes 48.5%
Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2030?Yes 47.5%
+3 moreNext deadline Jan 8, 2027 UTC
KalshiHealth
Will the FDA approve VERVE-102?

Will the FDA approve VERVE-102?

K 1.7K contracts
Will the FDA approve VERVE-102 before Jan 1, 2035?Yes 83.5%
Will the FDA approve VERVE-102 before Jan 1, 2034?Yes 79%
Will the FDA approve VERVE-102 before Jan 1, 2033?Yes 75.5%
+3 moreNext deadline Jan 8, 2030 UTC
KalshiHealth
Will the FDA approve retatrutide?

Will the FDA approve retatrutide?

K 69.5K contracts
When will the FDA approve retatrutide (LY3437943)? (Before Jan 1, 2029)Yes 89.5%
When will the FDA approve retatrutide (LY3437943)? (Before Jul 1, 2028)Yes 84.5%
When will the FDA approve retatrutide (LY3437943)? (Before Jan 1, 2028)Yes 70.5%
+2 moreNext deadline Jan 8, 2027 UTC
KalshiHealth
Will the FDA approve intismeran autogene (V940/mRNA-4157)?

Will the FDA approve intismeran autogene (V940/mRNA-4157)?

K 2.1K contracts
Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Jul 1, 2028?Yes 95%
Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Jan 1, 2028?Yes 87.5%
Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Oct 1, 2027?Yes 67.5%
+2 moreNext deadline Apr 8, 2027 UTC
PolymarketKalshiPolitics
When will Heidi Overton be confirmed as Commissioner of the FDA?

When will Heidi Overton be confirmed as Commissioner of the FDA?

PM $27.3K · K 18.6K contracts

Will Heidi Overton be confirmed as FDA Commissioner by December 31?

Kalshi: Will Heidi Overton be confirmed as Commissioner of the Food and Drug Administration before Jan 1, 2027?

Related contracts

PM Yes 45%Rules differK Yes 37.5%

Will Heidi Overton be confirmed as FDA Commissioner by November 30?

Kalshi: Will Heidi Overton be confirmed as Commissioner of the Food and Drug Administration before Dec 1, 2026?

Related contracts

PM Yes 5.5%Rules differK Yes 8.5%

Related or unreviewed contracts may settle differently. Their gap is not an equivalent-contract comparison.

Saved prices; check contract rules.

2 saved comparisonsNext deadline Nov 1, 2026 UTC

Market Insights

Price gaps of 2 pp+

0

Same-question pairs

0

No outcomes on this page have been reviewed as the same question on both platforms yet.

Price differences do not establish arbitrage. Check each pair's review, current order prices, fees and settlement rules.

Trade This Market

Trade on Polymarket